AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8827136
Drug: Centrifuge subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrifuge subjects at G-LOC endpoints
Trial: 1571611
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) administered within 8 hours of injury
Trial: 3907988
Drug: sulindac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulindac (200 mg twice daily)
Trial: 31246603
Drug: Prophylactic haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic haloperidol (1 or 2 mg)
Trial: 30251914
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment (14-16J/cm2) combined with Meibomian Gland Expression (MGX)
Trial: 30251914
Drug: Sham IPL
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham IPL treatment (0J/cm2)
Trial: 27344439
Drug: Dalteparin (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (subcutaneous 200 IU/kg once daily during month 1, followed by 150 IU/kg once daily for months 2-6)
Trial: 27344439
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) (once daily for 6 months, with initial overlapping subcutaneous dalteparin 200 IU/kg once daily for ≥5 days until INR was 2.0-3.0 for 2 consecutive days)
Trial: 22551881
Drug: Calcium-vitamin D3
RxNorm normalized name: Calcium/Cholecalciferol 600 MG-5 MCG Oral Capsule, Liquid Filled [CALCIUM-VITAMIN D3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin D3 fixed combination
Trial: 22551881
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D3 separate combination
Trial: 20861210
Drug: Polyphenols (PP)
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenols (PP) 50 mg
Trial: 20861210
Drug: Polyphenols (PP)
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenols (PP) 200 mg
Trial: 12819407
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (group 1, G1)
Trial: 12819407
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (group 2, G2)
Trial: 10625567
Drug: EMLA (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA (topical analgesia cream)
Trial: 31532004
Drug: Conventional hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hourly rate method (CM)
Trial: 26516810
Drug: Anticholinergic (AC)
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic (AC) treatment
Trial: 3666688
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) treatment
Trial: 27371428
Drug: ICG-PDT (Indocyanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 3 treatments over 2 weeks
Trial: 27371428
Drug: ICG-PDT (Indocyanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 5 treatments over 2 weeks
Trial: 18849616
Drug: Cluster SIT
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster SIT (14 injections of house dust mite allergen within 6 weeks)
Trial: 18849616
Drug: Classic SIT
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic SIT (14 injections of house dust mite allergen within 14 weeks)
Trial: 17093147
Drug: 11trans-18:1 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11trans-18:1 and 12trans-18:1 supplementation (3.0 g each per day for 6 weeks)
Trial: 11692118
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of epinephrine into the thigh
Trial: 11692118
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of epinephrine into the upper arm
Trial: 11692118
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of epinephrine into the upper arm
Trial: 31553500
Drug: Daily stressors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily stressors
Trial: 23064476
Drug: 5-mg of
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-mg of alendronate and 0.5-µg of calcitriol (Maxmarvil®)
Trial: 19920054
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (200 mg intravenous iron)
Trial: 16491287
Drug: Calcium- and
RxNorm normalized name: Calcium- and magnesium-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium- and vitamin D3-fortified milk (400 ml/day providing 1000 mg calcium and 800 IU vitamin D3)
Trial: 12760893
Drug: Telithromycin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telithromycin (800 mg once daily)
Trial: 12760893
Drug: Amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanic acid (1 g of amoxicillin and 125 mg of clavulanic acid 3 times daily)
Trial: 10690692
Drug: New low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New low-dose warfarin induction regimen
Trial: 8489296
Drug: Idarubicin 10
RxNorm normalized name: IDArubicin 10 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 10 mg/m2
Trial: 8489296
Drug: Idarubicin 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 12 mg/m2
Trial: 8489296
Drug: Idarubicin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 15 mg/m2
Trial: 8489296
Drug: Idarubicin in
RxNorm normalized name: idarubicin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin in patients with prior anthracycline therapy
Trial: 3813060
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg of intramuscular morphine 30‐60 min before induction
Trial: 29948896
Drug: fasting associated
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasting associated with intravenous heparin
Trial: 25093868
Drug: Hochuekkito (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hochuekkito (oral) for 24 weeks
Trial: 22382523
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (CMG) treated with Chinese herbs for supplementing qi, nourishing yin and activating blood circulation, besides Western medicine treatment.
Trial: 22382523
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (CMG)
Trial: 22382523
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (WMG)
Trial: 20669671
Drug: Chinese Medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Medicine internal-external combined therapy (ipratropium bromide aerosol, ambroxol hydrochloride, Chinese recipe, acupoint sticking with Xiaochuan Plaster)
Trial: 20669671
Drug: Atrovent Metered
RxNorm normalized name: ipratropium Metered Dose Inhaler [Atrovent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrovent Metered Dose Inhalation, oral Mucosolvan, Bailing Capsule, acupoint sticking with dummy plaster (Control)
Trial: 15944842
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (for two years)
Trial: 15944842
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of improved metabolic control and ACE inhibitor therapy
Trial: 6294433
Drug: Naloxone (opiate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (opiate receptor blockade)
Trial: 30382806
Drug: Walking+supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking+supplement
Trial: 26748734
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg and 750 mg
Trial: 17351155
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg tid for 10 days combined with a low-calorie diet
Trial: 15068431
Drug: Sub-Tenon infiltration
RxNorm normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Tenon infiltration with 3 mL of bupivacaine 0.50%
Trial: 15068431
Drug: Classical analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical analgesic drugs (control group)
Trial: 7835813
Drug: Abdomino-pelvic radiation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdomino-pelvic radiation therapy (APRT)
Trial: 27276742
Drug: Moringa Oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa Oleifera (MO) leaf at 0 g
Trial: 27276742
Drug: Moringa Oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa Oleifera (MO) leaf at 1 g
Trial: 27276742
Drug: Moringa Oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa Oleifera (MO) leaf at 2 g
Trial: 27276742
Drug: Moringa Oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa Oleifera (MO) leaf at 4 g
Trial: 27276742
Drug: Moringa Oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa Oleifera (MO) leaf at 4 g vs baseline (0 g)
Trial: 18536623
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine administered concomitantly with pneumococcal conjugate vaccine
Trial: 18536623
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine administered separately
Trial: 15813838
Drug: Antibiotic combination
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole for 2 weeks)
Trial: 15813838
Drug: No-antibiotics group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-antibiotics group
Trial: 6362702
Drug: Brotizolam 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.50 mg
Trial: 29950801
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) 7.5 mg intravenous dose
Trial: 24577124
Drug: Rivaroxaban 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10, 15, or 20 mg once daily
Trial: 24577124
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 or 150 mg twice daily
Trial: 20082712
Drug: 7.5% hypertonic
RxNorm normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% hypertonic saline in combination with 6% dextran‐70 (HSD)
Trial: 1985006
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of domperidone
Trial: 17586832
Drug: Standard GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard GnRH agonist long-protocol ovarian stimulation with double embryo transfer (n = 194)
Trial: 11107744
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan with autologous stem cell support
Trial: 8818844
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg tablets with food
Trial: 8818844
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg suspension with food
Trial: 8818844
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg sachet with food
Trial: 8818844
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg sachet (absolute bioavailability)
Trial: 1468240
Drug: etodolac SR
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: etodolac SR 600 mg daily
Trial: 1468240
Drug: etodolac SR
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: etodolac SR 1200 mg daily
Trial: 24277680
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (0.4 U/kg, single subcutaneous dose)
Trial: 19953628
Drug: Provox HiFlow
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provox HiFlow HME (L‐HME)
Trial: 17473095
Drug: High maternal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High maternal antibody levels in serum and breast milk
Trial: 15061863
Drug: Patient Information
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Information Leaflet (PIL) on oral cancer
Trial: 9665188
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of intensive chemotherapy (short arm)
Trial: 9665188
Drug: Eight cycles
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight cycles of intensive chemotherapy (long arm)
Trial: 10150267
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (1 dose)
Trial: 10150267
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (2 doses)
Trial: 10150267
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (6 doses)
Trial: 1064904
Drug: Rapidly-disintegrating tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly-disintegrating tablets with a standardized breakfast meal
Trial: 1064904
Drug: Slow-release tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release tablets with a standardized breakfast meal
Trial: 1064904
Drug: Rapidly-disintegrating tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly-disintegrating tablets under fasting conditions
Trial: 1064904
Drug: Slow-release tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release tablets under fasting conditions
Trial: 17915181
Drug: Computer-assisted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted cognitive training (20 sessions, 30-45 minutes each, twice a week)
Trial: 11563466
Drug: Vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal dinoprostone (2mg, two doses administered six hours apart)
Trial: 2686422
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin 200 mg twice daily
Trial: 2686422
Drug: Ceftazidime 1
RxNorm normalized name: ceftazidime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1 to 2 g every eight to 12 hours
Trial: 31053081
Drug: LOV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 30%)
Trial: 31053081
Drug: HOV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 80%)
Trial: 25872610
Drug: Losartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan treatment for 6 months
Trial: 25872610
Drug: Irbesartan treatment
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan treatment (in independent trials IDNT and IRMA-2)
Trial: 21488723
Drug: Desensitizing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing agent (5% potassium nitrate/2% sodium fluoride)
Trial: 19660004
Drug: Omalizumab (anti-IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (anti-IgE antibody), subcutaneously administered, dosage not specified, duration of treatment not specified.
Trial: 15244210
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Trial: 15244210
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Trial: 2794839
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (100 mg/cup)
Trial: 2794839
Drug: Caffeine capsules
RxNorm normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine capsules (100 mg/capsule)
Trial: 690226
Drug: Marijuana high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana high dose
Trial: 690226
Drug: Marijuana low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana low dose
Trial: 690226
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose marijuana in odor session
Trial: 690226
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose marijuana in odor session
Trial: 23177515
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg daily
Trial: 21295286
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg twice daily (n = 55)
Trial: 19369829
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (omeprazole 20 mg once daily, clarithromycin 250 mg twice daily, tinidazole 500 mg twice daily)
Trial: 19369829
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (among H. pylori eradicated patients)
Trial: 16688094
Drug: ARV +
RxNorm normalized name: Arv-110 (protac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV + HU (Hydroxyurea 500 mg BID)
Trial: 9255270
Drug: Alternating treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating treatments of CAV and PE
Trial: 31200280
Drug: Conservative medical
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative medical therapy
Trial: 27133564
Drug: YAB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YAB group (200 g of yoghurt supplemented with Bifidobacterium longum during both diet periods)
Trial: 20216071
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (luteal phase)
Trial: 18624972
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 1,000 mg alone
Trial: 18624972
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) + Dutasteride (D) 0.5 mg/die
Trial: 18624972
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) + Letrozole (L) 2.5 mg/die